Valeant filed with the Securities and Exchange Commission a presentation in connection with its written consent solicitation to stockholders of Cephalon, Inc. for removal of Cephalon's current Board of Directors and election of its seven nominees in their
News & Media
Premier Greg Selinger today announced the province is committing to invest $70 million in a new-state-of-the-art facility for CancerCare Manitoba to improve diagnostics, treatment and research that will help Manitoba families affected by this disease.
Valeant Pharmaceuticals International, Inc. announced that it had made a proposal to the Board of Directors of Cephalon, Inc. to acquire Cephalon for $73.00 per share in cash
Kane Biotech announced a non-brokered private placement offering for gross proceeds of up to $1,500,000 from the sale of up to 12,500,000 units at a price of $0.12 per unit
IMRISNV will provide important new capabilities for clinicians at University of Utah Hospital's leading edge stroke center
Valeant Pharmaceuticals International is Among the Companies in the Healthcare Sector With the Best Relative Performance
Valeant Pharmaceuticals International ranks first among companies in the Healthcare sector as measured by relative performance
A two-year-long clinical study on the health benefits of flax seeds is complete and, depending on the results, it could yield a rich supply of potential products for commercialization
The Governments of Canada and Manitoba are investing $400,000 to help survey Manitobans about their opinions, preferences and experiences with food and health which will lead to food development and creating a healthier future for Manitobans
Cangene returned to profitability in the second quarter with revenue up compared to the year before
Provincial and Federal Governments Commit More Than $406,000 to Agri-Health Research Network in Manitoba
The Governments of Canada and Manitoba are committing $406,000 in funding in 2010/11 to the Manitoba Agri-Health Research Network Inc. (MAHRN) to support the further research, development and commercialization of projects that identify links between food
The Governments of Canada and Manitoba announced they are contributing to a $10 million strategic initiative to enhance the capacity of the province’s medical device industry to develop and commercialize specialized joint replacement technology
DiaMedica announced antihypertensive results with its lead monoclonal antibody DM-204. Consistent and significant blood pressure lowering results are observed with DM-204 in all animals and the lower blood pressure occurred for the duration of the study
IMRIS Inc. announced the sale of IMRISneuro to the University Hospital Tübingen, located in Tübingen, Germany.
AstraZeneca PLC and Bristol-Myers Squibb Co. say their diabetes drug Onglyza has been approved in Europe for treating people with Type 2 diabetes who have moderate or severe renal impairment
Valeant Pharmaceuticals International, Inc. announces fourth quarter financial results for 2010.
Science Applications International Corporation (SAIC) announced it was awarded a contract extension by the National Aeronautics and Space Administration (NASA) for the Unified NASA Information Technology Services (UNITeS) contract
Kane Biotech has been named one of the top ten companies in the biotech industry by Fast Company in its annual list of the world’s “Most Innovative Companies.
The governments of Canada and Manitoba announced $2.6 million for the expansion of the Food Development Centre (FDC). Manitoba Agriculture, Food and Rural Initiatives (MAFRI) Minister Stan Struthers and Federal Member of Parliament Candice Hoeppner (Porta
The Manitoba government will assist the Pan Am Clinic in working with Echometrix LLC to assess the use of innovative ultrasound technology to diagnose and treat soft-tissue injuries and conditions, Innovation, Energy and Mines Minister Dave Chomiak announ
Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent (LOI) with PreMD Inc. to license the exclusive world
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company’s Research and Development (R&D) team has made contributions to two new scie